netFormulary Coventry and Warwickshire Area Prescribing Committee NHS
Formulary  
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
08.02.03  Expand sub section  Anti-lymphocyte monoclonal antibodies
Alemtuzumab
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of relapsing remitting multiple sclerosis with active disease
 
Link  NICE TA312: Alemtuzumab for treating relapsing‑remitting multiple sclerosis
   
Catumaxomab
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of malignant ascites in patients with epithelial cell adhesion molecule positive carcinomas
 
   
Daratumumab
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of relapsed and refractory multiple myeloma
 
Link  NICE TA510:Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
   
Obinutuzumab
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of leukaemia and lymphoma
 
Link  NICE TA343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia
Link  NICE TA513: Obinutuzumab for untreated advanced follicular lymphoma
   
Ofatumumab
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of chronic lymphocytic leukaemia
 
Link  NICE TA202: Chronic lymphocytic leukaemia - ofatumumab
Link  NICE TA344: Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia
   
Rituximab
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of lymphomas and chronic lymphocytic leukaemia, and anti-neutrophil cytoplasmic antibody-associated vasculitis


 
Link  NICE TA137: Lymphoma (follicular non-Hodgkin's) - rituximab
Link  NICE TA174: Leukaemia (chronic lymphocytic, first line) - rituximab
Link  NICE TA193: Leukaemia (chronic lymphocytic, relapsed) - rituximab
Link  NICE TA226: Lymphoma (follicular non-Hodgkin’s) - rituximab
Link  NICE TA243: Rituximab for the first-line treatment of stage III-IV follicular lymphomalymphoma
Link  NICE TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
   
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Blueteq
High Cost Drug Approval System

Traffic Light Status Information

Status Description

Preferred

Clinicians are free to prescribe these drugs. They are regarded as cost effective choices which have evidence to support their use.  

Second Line

These drugs should only be prescribed in the scenarios described in the formulary after preferred drug(s) have been ruled out.  

Non Formulary

Non-formulary choice - the vast majority of a patientís needs should be met by use of formulary preferred choices and second line options when appropriate. Therefore the Clinician should only use a non-formularly drug if this can be justified and it is recommended that all such instances are recorded in the patient record.  

Green SA

Specialist Advised Ė Specialists may simply advise a patientís GP to initiate these drugs themselves after they have made an initial assessment. Note: SA drugs can be initiated by the specialist according to patient need and also depending on local commissioning arrangements which may mandate, through the contract between provider and commissioner, that all SA drugs are treated as SI.  

Green SI

Specialist Initiation - These drugs must be initiated, i.e. the first dose prescribed, by the specialist and then may be continued when appropriate by the patientís GP following communication from the specialist.  

Amber SC

Shared Care - Responsibility for prescribing may be transferred from secondary to primary care with the agreement of an individual GP and when agreed shared care arrangements have been established. The specialist MUST stabilize the patient before asking for care to be transferred. Only specialists should initiate these drugs. Prescribing should be transferred to GPs according to an Shared Care Agreement [SCA]   

Red SO

Specialist Only - These drugs are deemed to be not appropriate for prescribing by GPs. Specialists should not ask GPs to prescribe these drugs.   

Black BL

Black Listed Medicines - These drugs are considered inappropriate for prescribing in Coventry & Warwickshire as they are either not cost-effective or of proven benefit or both.   

Not Recommended

Not Recommended - These are specialist drugs that are not recommended for use.  

netFormulary